Genetraks raises $6m
Wednesday, 18 December, 2002
Genetraks, a start-up biotech developing blood tests for use in pre-race evaluation of animals such as racehorses, has received a $6 million injection of venture capital.
The commercial potential of its technology for assessing the health of racing animals with a view to maximising their performance has helped the company win investment interest in a difficult market.
The Brisbane company, which received earlier support from St George Innovation Fund and a $246,380 Biotechnology Innovation Fund (BIF) grant, is based on bioinformatics techniques. Its technology relates to the diagnostic capacity of gene expression 'signatures' in white blood cells in immune-mediated diseases.
The company is led by two veterinary PhDs, Rosalyn and Richard Brandon, who respectively are its CEO and biotechnology director.
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
